查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1839061

细胞治疗技术市场：按产品、治疗类型、生产流程、给药方式、应用和最终用户划分－2025-2032年全球预测

Cell Therapy Technologies Market by Offering, Therapy Type, Manufacturing Process, Delivery Method, Application, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，细胞治疗技术市场将成长至 136.8 亿美元，复合年增长率为 14.41%。

主要市场统计数据
基准年 2024 46.6亿美元
预计年份：2025年 52.9亿美元
预测年份：2032年 136.8亿美元
复合年增长率 (%) 14.41%

一个权威的框架，用于说明科学突破、製造现实和商业性动态如何融合，从而製定细胞疗法商业化的议程。

细胞疗法正从实验性干预发展成为一种结构化的临床和商业性模式，挑战传统的製药模式。过去十年，细胞来源、基因改造和自动化生产的科学进步，与新的监管管道和不断扩大的临床证据相融合，拓展了细胞疗法的适应症范围。这一发展进程是由当前的生态系统推动的，该生态系统认识到，仅靠技术创新并不能保证应用；可生产性、品质系统、报销策略以及可靠的供应链组装能力同样至关重要。

在取得突破性的临床里程碑之后，相关人员目前关注的重点是流程的可重复性、交货成本以及确保产品可追溯性和患者安全的资料系统整合。投资者和策略合作伙伴正在评估该平台在不同治疗方法类型、给药方式和终端用户环境中的适用性。因此，业界正朝着模组化解决方案的方向发展，将耗材、专用设备和软体服务结合，以缩短週期时间并提高可重复性。这种应用为后续分析奠定了基础，凸显了科学、製造、监管和商业领域之间的相互依存关係，强调了跨职能规划的必要性，以将技术前景转化为对患者的持续影响。

自动化、资料管理和治疗方式的进步如何重塑细胞治疗生态系统的生产模式和商业策略？

细胞治疗领域正从多个维度发生变革，重新定义竞争优势和营运重点。向临床阶段的过渡推动生产流程从单一地点、小批量生产转向可扩展、标准化的生产模式，强调自动化和封闭式系统。这种转变降低了操作人员的差异性，加快了产品上市速度，同时也让人们更加关注设备的互通性和耗材的标准化。同时，数据管理层正逐渐成为一项策略资产。能够实现批次级追溯、品管分析和法规文件编制的软体和服务，对于提升营运韧性至关重要。

在治疗方面，从本土研发的第一代产品转向异体和基因工程治疗方法正在重塑供应链设计和商业性思维。异体移植方法提升了上游供体来源和库存策略的重要性，而基因修饰平台则拓展了细胞治疗生产商和分子生物学供应商之间的联繫。临床试验和生产设施的区域分散化也是一个变革性趋势，其驱动因素包括人才取得、成本差异和监管环境。总而言之，这些转变标誌着一个日趋成熟的行业，该行业必须在科学创新、可重复生产和商业性规模化之间取得平衡，以确保更广泛的患者群体能够获得治疗。

2025 年前美国关税政策演变的影响，以及供应链策略和资本计画应如何调整以降低累积风险。

预计2025年美国关税政策的变化将带来多重地缘政治和成本风险，相关人员必须积极应对。影响进口设备、专用耗材和原材料的关税可能导致资本计划延期和单剂製造成本上升，即使企业试图消化短期影响。要更理解其累积影响，最好透过情境规划，将投入品采购、製造外包关係、库存策略等因素纳入考量。在受关税影响的情况下，拥有多元化供应商网路和本土生产选择的企业将更具优势，而依赖单一进口管道的企业则可能面临营运中断。

监管和采购团队应评估供应商合约中的不可抗力条款和价格弹性，而商务负责人应更新报销模式以反映潜在的成本上涨。策略因应措施包括加速国内供应商的资质认证，采用模组化生产以减少对大规模进口组件的依赖，以及投资于降低单次用药耗材强度的技术。同时，企业发展部门应重新评估跨境伙伴关係，并考虑选择能减轻关税影响的区域性製造地。将关税情境纳入资本规划和供应商风险评估，有助于企业维持计划进度，并保护利润免受政策突变的影响。

全面的细分洞察揭示了细胞治疗价值链中策略重点是如何透过产品、治疗类型、生产流程、给药方式、应用和最终用户来确定的。

我们的分析揭示了能够最有效地加速您专案进展的投资和营运重点。耗材支援日常细胞处理和试剂一致性，反应器和细胞分析仪等设备可实现规模化和流程控制，而专注于资料管理和品管的软体和服务则为可追溯性和法规遵循提供了数位化基础。这些层面相互依存；设备的选择会影响您的耗材用量，而资料系统对于检验製程效能至关重要。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 针对固态肿瘤抗药性机制的同种异体CAR-T细胞疗法的研究进展
  • 创新非病毒基因组编辑平台，实现可扩展的细胞治疗生产流程
  • 现成的自然杀手细胞疗法的出现，可快速产生免疫肿瘤治疗反应
  • 在细胞治疗规模化生产过程中，整合自动化封闭式反应器以降低生产成本
  • FDA和EMA之间的监管协调倡议旨在加速细胞疗法的市场核准
  • 利用人工智慧建模预测细胞生长和疗效结果
  • 针对罕见癌症抗原的个人化T细胞受体修饰治疗方法的开发
  • 利用诱导性多功能干细胞进行同种异体再生医学治疗神经退化性疾病
  • 透过生技公司与合约研发生产力机构（CDMO）之间的策略联盟，加强全球细胞疗法供应链。

第六章美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 细胞治疗技术市场（依产品/服务分类）

  • 消耗品
  • 装置
    • 反应器
    • 细胞分析仪
  • 软体和服务
    • 资料管理
    • 品管

第九章 依治疗类型分類的细胞治疗技术市场

  • 异体细胞疗法
    • 树突状细胞
    • 诱导性多功能细胞
    • 自然杀手细胞
  • 自体细胞疗法
    • 造血干细胞
    • 间质干细胞
    • T细胞
  • 基因改造细胞疗法
    • CAR-T细胞疗法
    • TCR（T细胞受体）疗法

第十章 依製造流程分類的细胞治疗技术市场

  • 细胞培养
    • 二维文化系统
    • 3D培养系统
  • 细胞增殖
    • 依附文化
    • 悬浮培养
  • 细胞分离
    • 萤光活化细胞分选
    • 磁激活细胞分选

第十一章 细胞治疗技术市场：依给药方式划分

  • Ex vivo
  • In vivo

第十二章 细胞治疗技术市场：依应用领域划分

  • 心血管疾病
    • 缺血性心臟疾病
    • 周边动脉疾病
  • 肌肉骨骼疾病
    • 骨关节炎
    • 类风湿性关节炎
  • 神经退化性疾病
    • 阿兹海默症
    • 帕金森氏症
  • 瘤
    • 血癌
    • 固态肿瘤
      • 乳癌
      • 肺癌
      • 摄护腺癌

第十三章 依最终用户分類的细胞治疗技术市场

  • 生物製药公司
  • 医院
    • 私立医院
    • 公立医院
  • 研究所
    • 政府研究中心
    • 大学学术机构

第十四章 细胞治疗技术市场（按地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章 细胞治疗技术市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 各国细胞治疗技术市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Allogene Therapeutics Inc.
    • Atara BIoTherapeutics, Inc.
    • Century Therapeutics, Inc.
    • Charles River Laboratories International, Inc.
    • Gamida Cell Ltd.
    • GE HealthCare
    • Gilead Sciences, Inc.
    • Johnson & Johnson Services, Inc.
    • Novartis AG
    • Sartorius AG
    • Takara Bio Inc.
    • Takeda Pharmaceutical Company Limited
    • Thermo Fisher Scientific Inc.
    • Vericel Corporation
Product Code: MRR-034230D3E636

The Cell Therapy Technologies Market is projected to grow by USD 13.68 billion at a CAGR of 14.41% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 4.66 billion
Estimated Year [2025] USD 5.29 billion
Forecast Year [2032] USD 13.68 billion
CAGR (%) 14.41%

An authoritative framing of how scientific breakthroughs, manufacturing realities, and commercial dynamics converge to set the agenda for cell therapy commercialization

Cell therapies are evolving from experimental interventions into structured clinical and commercial paradigms that challenge conventional pharmaceutical models. Over the past decade, scientific advances in cell sourcing, genetic modification, and automated manufacturing have converged with new regulatory pathways and expanding clinical evidence to broaden the set of indications addressed by cell-based interventions. This introduction frames the current ecosystem by acknowledging that technical innovation alone does not guarantee adoption; equally important are manufacturability, quality systems, reimbursement strategy, and the ability to scale supply chains reliably.

In the wake of transformative clinical milestones, stakeholders now focus on the repeatability of processes, cost-to-deliver, and integration of data systems that ensure product traceability and patient safety. Investors and strategic partners increasingly assess platform applicability across therapy types, delivery methods, and end-user contexts. The industry is therefore transitioning toward modular solutions that combine consumables, specialized equipment, and software-enabled services to reduce cycle times and improve reproducibility. This introduction sets the scene for subsequent analysis by highlighting interdependencies across scientific, manufacturing, regulatory, and commercial domains, and underscores the imperative for cross-functional planning to convert technological promise into durable patient impact.

How advances in automation, data management, and therapeutic modality evolution are reshaping manufacturing models and commercial strategies across the cell therapy ecosystem

The landscape for cell therapies is shifting along multiple axes that will redefine competitive advantage and operational priorities. Clinical translation is driving a move from single-center, small-batch workflows toward scalable, standardized manufacturing approaches that emphasize automation and closed systems. This shift reduces operator variability and shortens time-to-release, but it also concentrates attention on equipment interoperability and consumable standardization. Concurrently, data management layers are emerging as strategic assets: software and services that enable batch-level traceability, quality control analytics, and regulatory-ready documentation are becoming essential to operational resilience.

Therapeutically, the sequence from autologous first-generation products to allogeneic and gene-modified modalities is reshaping supply chain design and commercial thinking. Allogeneic approaches increase the importance of upstream donor sourcing and inventory strategies, while gene-modified platforms expand the interface between cell therapy manufacturers and molecular biology suppliers. Geographic diversification of clinical trials and manufacturing facilities is another transformative trend, motivated by talent access, cost differentials, and regulatory landscapes. Taken together, these shifts signal a maturing industry that must balance scientific innovation with reproducible manufacturing and commercial scalability to unlock broader patient access.

Scenario-based implications of evolving United States tariffs for 2025 and how supply chain strategies and capital planning must adapt to mitigate cumulative risk

Anticipated changes in United States tariff policy for 2025 introduce a layer of geopolitical and cost risk that stakeholders must manage proactively. Tariffs that affect imported equipment, specialized consumables, or raw materials can translate into delayed capital projects and higher per-dose manufacturing costs, even when organizations seek to absorb short-term impacts. The cumulative effect is best understood through scenario planning that considers input sourcing, contract manufacturing relationships, and inventory strategies. In tariffs-impacted scenarios, firms with diversified supplier networks and onshore manufacturing options will be favored, while those reliant on single-source import channels may face operational disruptions.

Regulatory and procurement teams should evaluate supplier contracts for force majeure and pricing flexibility, while commercial leads should update reimbursement models to reflect potential cost inflation. Strategic responses include accelerating qualification of domestic suppliers, modularizing manufacturing to reduce reliance on large imported assemblies, and investing in technologies that lower consumable intensity per dose. In parallel, corporate development functions should reassess cross-border partnerships and consider regional manufacturing hubs that mitigate tariff exposure. By integrating tariff scenarios into capital planning and supplier risk assessments, organizations can preserve project timelines and protect margins against abrupt policy shifts.

Comprehensive segmentation insights showing how offerings, therapy types, manufacturing processes, delivery methods, applications, and end users define strategic priorities across the cell therapy value chain

Segmentation-driven insight reveals where investments and operational focus will most effectively accelerate program advancement. Based on offering, it is essential to recognize how consumables, equipment, and software and services play complementary roles: consumables underpin day-to-day cell handling and reagent consistency, equipment such as bioreactors and cell analyzers enable scale and process control, and software and services focused on data management and quality control provide the digital backbone for traceability and regulatory compliance. These layers are interdependent; equipment choices influence consumable footprints, and data systems are necessary to validate process performance.

Based on therapy type, differentiation between allogeneic cell therapy, autologous cell therapy, and gene-modified cell therapy determines manufacturing architecture. Allogeneic modalities, including dendritic cells, induced pluripotent stem cells, and natural killer cells, prioritize donor sourcing and batch banking approaches. Autologous therapies, such as hematopoietic stem cells, mesenchymal stem cells, and T-cells, demand patient-matched logistics and agile closed systems. Gene-modified treatments, exemplified by CAR-T and TCR therapies, layer genetic engineering steps that require integrated vector production and stringent quality control.

Based on manufacturing process, attention to cell culture, expansion, and separation illuminates capital and skills requirements. Cell culture systems that include 2D and 3D platforms drive upstream process design, while cell expansion choices between adherent and suspension culture affect scale economics. Cell separation technologies such as fluorescence-activated cell sorting and magnetic-activated cell sorting underpin purity and potency metrics. Based on delivery method, the ex vivo and in vivo dichotomy shapes cold-chain needs, administration logistics, and clinical workflow integration. Based on application, therapeutic focus across cardiovascular disease, musculoskeletal disorders, neurodegenerative diseases, and oncology informs target product profiles and clinical development pathways, with further granularity across ischemic heart disease, peripheral artery disease, osteoarthritis, rheumatoid arthritis, Alzheimer's disease, Parkinson's disease, hematological cancer, and a range of solid tumors including breast, lung, and prostate cancers influencing clinical endpoint selection. Based on end user, the ecosystem of biopharmaceutical companies, hospitals, and research institutes-where hospitals may be private or public and research institutes include government research centers and university academics-creates diverse procurement cycles and operational capabilities that must be matched by suppliers seeking commercial traction.

How regional regulatory nuance, clinical networks, and infrastructure strengths across the Americas, Europe Middle East & Africa, and Asia-Pacific inform where to invest and localize capabilities

Regional context materially affects strategic choices for development, manufacturing, and market access. In the Americas, advanced clinical trial networks, established reimbursement mechanisms for advanced therapies, and a concentration of venture and corporate capital support rapid translation, but stakeholders must also navigate complex payer dynamics and regional regulatory nuance. Europe, Middle East & Africa presents heterogeneous regulatory regimes and reimbursement environments where centralized approvals can coexist with country-level access barriers, creating an imperative for localized engagement and adaptive pricing strategies. In Asia-Pacific, growing government support, investments in manufacturing infrastructure, and talent development are accelerating regional capability, though intellectual property considerations and local regulatory maturity vary widely.

Given these differences, companies should align site selection, clinical trial designs, and partnership models to regional strengths. Manufacturing footprints can be hybrid: using near-market capacity in the Americas for rapid commercial launches, leveraging EMEA partners for regulatory alignment and access to diverse patient populations, and establishing scaled capabilities in Asia-Pacific to benefit from growing clinical demand and cost efficiencies. Cross-border coordination of regulatory submissions, supply chain logistics, and commercial strategy will be critical to sustain global programs and minimize time-to-patient across jurisdictions.

Patterns in company strategies and partnership models showing how integrated capabilities, outsourcing decisions, and regulatory engagement shape competitive advantage in cell therapy

Insights into company behavior reveal patterns that will influence competitive dynamics and partnership opportunities. Leading organizations increasingly combine in-house capabilities with strategic outsourcing to balance control and speed; they retain core competencies in process development and quality assurance while partnering for vector production, fill-finish, or specialized analytics. Companies that invest early in modular, automation-friendly equipment and harmonized data systems achieve faster tech transfer and reduce variability across sites. This capability set also attracts collaborators that seek predictable scale-up pathways.

Smaller innovators tend to concentrate on platform differentiation and clinical proof-of-concept while relying on contract development and manufacturing organizations for production. Strategic acquirers and corporate venture arms favor platforms that de-risk manufacturing or improve cost of goods, making manufacturing-focused technologies and quality automation attractive targets. Across the ecosystem, suppliers that offer integrated solutions-combining consumables, validated equipment, and quality-ready software-are best positioned to enter long-term supply agreements. Lastly, companies emphasizing regulatory engagement and early payer dialogue demonstrate higher resilience in navigating post-approval access challenges.

Actionable strategic priorities to fortify manufacturing resilience, accelerate market access, and de-risk commercialization through targeted investments and partnerships

Industry leaders must translate insight into prioritized actions that reduce operational risk and accelerate commercialization. First, align capital investments with modular automation and validated equipment that enable replication across sites, thereby lowering tech transfer friction and supporting rapid scale-up. Second, formalize supplier diversification strategies and qualify domestic alternatives for critical consumables and equipment subcomponents to mitigate geopolitical and tariff-related disruption. Third, invest in robust data management and quality control systems that support batch release, regulatory submissions, and traceability across decentralized manufacturing networks.

Additionally, pursue strategic partnerships that close capability gaps without diluting core intellectual property, and coordinate early with payers and regulatory authorities to define evidentiary pathways that reflect real-world use cases. Prioritize workforce development programs that upskill operators and quality professionals in cell therapy-specific practices, and create cross-functional commercialization playbooks that tie clinical development milestones to manufacturing scale triggers. Finally, adopt scenario-based financial planning that models supply chain shocks, reimbursement variability, and capital deployment options so that leadership teams can make decisive moves under uncertainty.

An explainable and reproducible methodology integrating executive interviews, secondary evidence, and cross-validation to underpin actionable recommendations for cell therapy stakeholders

The research methodology underpinning this analysis blends primary engagement with subject-matter experts and structured secondary synthesis to ensure both depth and practical relevance. Primary inputs include in-depth interviews with senior manufacturing leaders, quality assurance executives, clinical operations heads, and commercial strategy professionals from developers, contract manufacturers, and hospital systems. These conversations probe operational constraints, technology adoption drivers, and decision criteria that shape supplier selection. Secondary sources comprise scientific literature, regulatory guidance documents, company technical disclosures, and industry white papers used to validate technology feasibility and regulatory pathways.

Data triangulation reconciles qualitative insights with documented process descriptions and public regulatory filings. The approach emphasizes reproducibility by cross-checking vendor claims against independent technical evaluations and by capturing divergent viewpoints where consensus does not exist. Quality assurance workflows include peer review by analysts with process engineering and regulatory experience, and sensitivity checks that surface assumptions underpinning strategic recommendations. Where appropriate, limitations and potential bias are noted, and recommendations carry clear implementation considerations so that decision-makers can adapt findings to their specific organizational context.

A strategic synthesis demonstrating that durable success in cell therapy requires the integration of scientific innovation, manufacturing discipline, and market-aligned commercialization planning

In conclusion, the cell therapy sector stands at an inflection point where scientific maturity is converging with operational discipline and commercial pragmatism. The path to broader patient access requires more than therapeutic novelty; it demands manufacturing reproducibility, digitally enabled quality systems, and supply chains designed to withstand geopolitical and policy shifts. Stakeholders that synchronize investments in consumables, equipment, and software with therapy-specific manufacturing choices will realize faster and more reliable program progression.

Moreover, regional strategy, company-level partnership models, and proactive payer engagement will determine the pace of adoption across indications. By emphasizing modular automation, diversified sourcing, and data-driven quality control, organizations can reduce execution risk and improve the odds of sustainable commercialization. The cumulative message is clear: success in cell therapy will be driven by integrative strategies that connect scientific innovation to operational excellence and market-focused commercialization plans. This conclusion should guide leadership teams as they prioritize near-term investments and longer-term capability building.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Advancements in allogeneic CAR-T cell therapies targeting solid tumor resistance mechanisms
  • 5.2. Innovations in non-viral genome editing platforms for scalable cell therapy manufacturing workflows
  • 5.3. Emerging off-the-shelf natural killer cell therapies for rapid immuno-oncology treatment response
  • 5.4. Integration of automated closed system bioreactors to reduce production costs in cell therapy scale-up
  • 5.5. Regulatory harmonization initiatives between FDA and EMA for expedited cell therapy market authorizations
  • 5.6. Application of artificial intelligence for predictive modeling of cell expansion and potency outcomes
  • 5.7. Development of personalized T cell receptor engineered therapies for targeting rare oncogenic antigens
  • 5.8. Use of induced pluripotent stem cells in allogeneic regenerative treatments for neurodegenerative diseases
  • 5.9. Strategic collaborations between biotech companies and CDMOs to strengthen global cell therapy supply chains

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cell Therapy Technologies Market, by Offering

  • 8.1. Consumables
  • 8.2. Equipment
    • 8.2.1. Bioreactors
    • 8.2.2. Cell Analyzers
  • 8.3. Software & Services
    • 8.3.1. Data Management
    • 8.3.2. Quality Control

9. Cell Therapy Technologies Market, by Therapy Type

  • 9.1. Allogeneic Cell Therapy
    • 9.1.1. Dendritic Cells
    • 9.1.2. Induced Pluripotent Stem Cells
    • 9.1.3. Natural Killer Cells
  • 9.2. Autologous Cell Therapy
    • 9.2.1. Hematopoietic Stem Cells
    • 9.2.2. Mesenchymal Stem Cells
    • 9.2.3. T-Cells
  • 9.3. Gene-Modified Cell Therapy
    • 9.3.1. CAR-T Cell Therapy
    • 9.3.2. TCR (T-Cell Receptor) Therapy

10. Cell Therapy Technologies Market, by Manufacturing Process

  • 10.1. Cell Culture
    • 10.1.1. 2D Culture Systems
    • 10.1.2. 3D Culture Systems
  • 10.2. Cell Expansion
    • 10.2.1. Adherent Culture
    • 10.2.2. Suspension Culture
  • 10.3. Cell Separation
    • 10.3.1. Fluorescence-Activated Cell Sorting
    • 10.3.2. Magnetic-Activated Cell Sorting

11. Cell Therapy Technologies Market, by Delivery Method

  • 11.1. Ex vivo
  • 11.2. In vivo

12. Cell Therapy Technologies Market, by Application

  • 12.1. Cardiovascular Disease
    • 12.1.1. Ischemic Heart Disease
    • 12.1.2. Peripheral Artery Disease
  • 12.2. Musculoskeletal Disorders
    • 12.2.1. Osteoarthritis
    • 12.2.2. Rheumatoid Arthritis
  • 12.3. Neurodegenerative Diseases
    • 12.3.1. Alzheimer's Disease
    • 12.3.2. Parkinson's Disease
  • 12.4. Oncology
    • 12.4.1. Hematological Cancer
    • 12.4.2. Solid Tumors
      • 12.4.2.1. Breast Cancer
      • 12.4.2.2. Lung Cancer
      • 12.4.2.3. Prostate Cancer

13. Cell Therapy Technologies Market, by End User

  • 13.1. Biopharmaceutical Companies
  • 13.2. Hospitals
    • 13.2.1. Private Hospitals
    • 13.2.2. Public Hospitals
  • 13.3. Research Institutes
    • 13.3.1. Government Research Centers
    • 13.3.2. University Academics

14. Cell Therapy Technologies Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Cell Therapy Technologies Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Cell Therapy Technologies Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Allogene Therapeutics Inc.
    • 17.3.2. Atara Biotherapeutics, Inc.
    • 17.3.3. Century Therapeutics, Inc.
    • 17.3.4. Charles River Laboratories International, Inc.
    • 17.3.5. Gamida Cell Ltd.
    • 17.3.6. GE HealthCare
    • 17.3.7. Gilead Sciences, Inc.
    • 17.3.8. Johnson & Johnson Services, Inc.
    • 17.3.9. Novartis AG
    • 17.3.10. Sartorius AG
    • 17.3.11. Takara Bio Inc.
    • 17.3.12. Takeda Pharmaceutical Company Limited
    • 17.3.13. Thermo Fisher Scientific Inc.
    • 17.3.14. Vericel Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY OFFERING, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY OFFERING, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY THERAPY TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MANUFACTURING PROCESS, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MANUFACTURING PROCESS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY DELIVERY METHOD, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY DELIVERY METHOD, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE CELL THERAPY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST CELL THERAPY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC CELL THERAPY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN CELL THERAPY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC CELL THERAPY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION CELL THERAPY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS CELL THERAPY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 CELL THERAPY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO CELL THERAPY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. CELL THERAPY TECHNOLOGIES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. CELL THERAPY TECHNOLOGIES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CELL THERAPY TECHNOLOGIES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CONSUMABLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CONSUMABLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CONSUMABLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY EQUIPMENT, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY EQUIPMENT, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY EQUIPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY EQUIPMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY EQUIPMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY EQUIPMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY EQUIPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY EQUIPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY BIOREACTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY BIOREACTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY BIOREACTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY BIOREACTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY BIOREACTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY BIOREACTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL ANALYZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL ANALYZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL ANALYZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL ANALYZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL ANALYZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL ANALYZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY DATA MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY DATA MANAGEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY DATA MANAGEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY DATA MANAGEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY DATA MANAGEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY DATA MANAGEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY QUALITY CONTROL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY QUALITY CONTROL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY QUALITY CONTROL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY QUALITY CONTROL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY QUALITY CONTROL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY QUALITY CONTROL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ALLOGENEIC CELL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ALLOGENEIC CELL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ALLOGENEIC CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ALLOGENEIC CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ALLOGENEIC CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ALLOGENEIC CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ALLOGENEIC CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ALLOGENEIC CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY DENDRITIC CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY DENDRITIC CELLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY DENDRITIC CELLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY DENDRITIC CELLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY DENDRITIC CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY DENDRITIC CELLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY INDUCED PLURIPOTENT STEM CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY INDUCED PLURIPOTENT STEM CELLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY INDUCED PLURIPOTENT STEM CELLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY INDUCED PLURIPOTENT STEM CELLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY INDUCED PLURIPOTENT STEM CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY INDUCED PLURIPOTENT STEM CELLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY NATURAL KILLER CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY NATURAL KILLER CELLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY NATURAL KILLER CELLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY NATURAL KILLER CELLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY NATURAL KILLER CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY NATURAL KILLER CELLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY AUTOLOGOUS CELL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY AUTOLOGOUS CELL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY AUTOLOGOUS CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY AUTOLOGOUS CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY AUTOLOGOUS CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY AUTOLOGOUS CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY AUTOLOGOUS CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY AUTOLOGOUS CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MESENCHYMAL STEM CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MESENCHYMAL STEM CELLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MESENCHYMAL STEM CELLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MESENCHYMAL STEM CELLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MESENCHYMAL STEM CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MESENCHYMAL STEM CELLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY T-CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY T-CELLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY T-CELLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY T-CELLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY T-CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY T-CELLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY GENE-MODIFIED CELL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY GENE-MODIFIED CELL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY GENE-MODIFIED CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY GENE-MODIFIED CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY GENE-MODIFIED CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY GENE-MODIFIED CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY GENE-MODIFIED CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY GENE-MODIFIED CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CAR-T CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CAR-T CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CAR-T CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CAR-T CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CAR-T CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CAR-T CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY TCR (T-CELL RECEPTOR) THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY TCR (T-CELL RECEPTOR) THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY TCR (T-CELL RECEPTOR) THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY TCR (T-CELL RECEPTOR) THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY TCR (T-CELL RECEPTOR) THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY TCR (T-CELL RECEPTOR) THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MANUFACTURING PROCESS, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL CULTURE, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL CULTURE, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL CULTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL CULTURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL CULTURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL CULTURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL CULTURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL CULTURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY 2D CULTURE SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY 2D CULTURE SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY 2D CULTURE SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY 2D CULTURE SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY 2D CULTURE SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY 2D CULTURE SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY 3D CULTURE SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY 3D CULTURE SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY 3D CULTURE SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY 3D CULTURE SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY 3D CULTURE SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY 3D CULTURE SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL EXPANSION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL EXPANSION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL EXPANSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL EXPANSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL EXPANSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL EXPANSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL EXPANSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL EXPANSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ADHERENT CULTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ADHERENT CULTURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ADHERENT CULTURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ADHERENT CULTURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ADHERENT CULTURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ADHERENT CULTURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SUSPENSION CULTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SUSPENSION CULTURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SUSPENSION CULTURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SUSPENSION CULTURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SUSPENSION CULTURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SUSPENSION CULTURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL SEPARATION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL SEPARATION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL SEPARATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL SEPARATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL SEPARATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL SEPARATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL SEPARATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL SEPARATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY FLUORESCENCE-ACTIVATED CELL SORTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY FLUORESCENCE-ACTIVATED CELL SORTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY FLUORESCENCE-ACTIVATED CELL SORTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY FLUORESCENCE-ACTIVATED CELL SORTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY FLUORESCENCE-ACTIVATED CELL SORTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY FLUORESCENCE-ACTIVATED CELL SORTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MAGNETIC-ACTIVATED CELL SORTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MAGNETIC-ACTIVATED CELL SORTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MAGNETIC-ACTIVATED CELL SORTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MAGNETIC-ACTIVATED CELL SORTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MAGNETIC-ACTIVATED CELL SORTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MAGNETIC-ACTIVATED CELL SORTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY EX VIVO, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY EX VIVO, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY EX VIVO, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY EX VIVO, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY EX VIVO, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY EX VIVO, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY IN VIVO, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY IN VIVO, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY IN VIVO, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY IN VIVO, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY IN VIVO, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY IN VIVO, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CARDIOVASCULAR DISEASE, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CARDIOVASCULAR DISEASE, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CARDIOVASCULAR DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CARDIOVASCULAR DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CARDIOVASCULAR DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CARDIOVASCULAR DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CARDIOVASCULAR DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CARDIOVASCULAR DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ISCHEMIC HEART DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ISCHEMIC HEART DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ISCHEMIC HEART DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ISCHEMIC HEART DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ISCHEMIC HEART DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ISCHEMIC HEART DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY OSTEOARTHRITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY OSTEOARTHRITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY OSTEOARTHRITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY OSTEOARTHRITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY OSTEOARTHRITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY OSTEOARTHRITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY NEURODEGENERATIVE DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY NEURODEGENERATIVE DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY NEURODEGENERATIVE DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY NEURODEGENERATIVE DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY NEURODEGENERATIVE DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY NEURODEGENERATIVE DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ALZHEIMER'S DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ALZHEIMER'S DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ALZHEIMER'S DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ALZHEIMER'S DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY PARKINSON'S DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY PARKINSON'S DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY PARKINSON'S DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY PARKINSON'S DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY HEMATOLOGICAL CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY HEMATOLOGICAL CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY HEMATOLOGICAL CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY HEMATOLOGICAL CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY HEMATOLOGICAL CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY HEMATOLOGICAL CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOLID TUMORS, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOLID TUMORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY BREAST CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 289. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 290. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY BREAST CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 291. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY BREA